Suzanne E Dahlberg

A Proportional Hazards Cure Model for the Analysis of Time to Event with Frequently Unidentifiable Causes

Molin Wang, Suzanne E Dahlberg, Molin Wang, 2007, Biometrics.

Improving Clinical Trial Efficiency: Thinking outside the Box.

Richard Simon, Sumithra J Mandrekar, Suzanne E Dahlberg, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.

Suzanne E Dahlberg, Geoffrey R Oxnard, C. Paweletz, 2016, JAMA oncology.

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Hiroto Hatabu, Suzanne E Dahlberg, Bruce E Johnson, 2012, Lung cancer.

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Suzanne E Dahlberg, Bruce E Johnson, Geoffrey R Oxnard, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Caroline Domerg, Stefan Michiels, Herbert Pang, 2013, The Lancet. Oncology.